Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain

被引:7
作者
Velkov, Tony [1 ,2 ]
Rimmer, Kieran A. [2 ]
Headey, Stephen J. [2 ]
机构
[1] Deakin Univ, Sch Med, Geelong, Vic 3217, Australia
[2] Monash Univ, Dept Med Chem & Drug Act, Monash Inst Pharmaceut Sci, Parkville, Vic 3052, Australia
关键词
Peroxisome proliferator-activated receptor alpha ligand binding domain; Nuclear hormone receptor; Ligand-enhanced protein expression; REGULATE GENE-EXPRESSION; FATTY-ACIDS; HIGH-AFFINITY; NUCLEAR RECEPTORS; RETINOIC-ACID; BETA-OXIDATION; PPARS; EICOSANOIDS; COACTIVATORS; SELECTIVITY;
D O I
10.1016/j.pep.2009.09.012
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A human peroxisome proliferator-activated receptor alpha ligand binding domain (PPAR alpha LBD)-maltose binding protein fusion construct was expressed in Escherichia coli. A codon optimized DNA sequence encoding human PPAR alpha LBD (aa196-468) was synthesized and ligated into the pDEST17 E. coli expression vector downstream of a MBP solubility fusion tag and an intermittent TEV protease cleavage site. Following auto-induction at 28 degrees C, PPAR alpha LBD protein was purified to electrophoretic homogeneity by a nickel affinity chromatographic step, on-column TEV protease cleavage followed by Sephacryl S200 size exclusion chromatography. The recombinant protein displayed cross-reactivity with goat anti-(human PPAR alpha) polyclonal antibody and was identified as human PPAR alpha by trypic peptide mass finger-printing. The addition of a PPAR alpha specific ligand (fenofibric acid, GW7647 or GW590735) to the growth media significantly stabilized the PPAR alpha LBD structure and enhanced the expression of soluble protein. In-cell ligand binding was examined by monitoring the enhancement of PPAR alpha LBD expression as a function of the concentration of ligand in the growth media. The efficient expression and in-cell assay of the reported PPAR alpha LBD construct make it amenable to high through-put screening assays in drug discovery programs. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:260 / 269
页数:10
相关论文
共 34 条
[31]   The PPARs: From orphan receptors to drug discovery [J].
Willson, TM ;
Brown, PJ ;
Sternbach, DD ;
Henke, BR .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (04) :527-550
[32]   Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors [J].
Xu, HE ;
Lambert, MH ;
Montana, VG ;
Plunket, KD ;
Moore, LB ;
Collins, JB ;
Oplinger, JA ;
Kliewer, SA ;
Gampe, RT ;
McKee, DD ;
Moore, JT ;
Willson, TM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (24) :13919-13924
[33]   Nuclear receptors have distinct affinities for coactivators: Characterization by fluorescence resonance energy transfer [J].
Zhou, GC ;
Cummings, R ;
Li, Y ;
Mitra, S ;
Wilkinson, HA ;
Elbrecht, A ;
Hermes, JD ;
Schaeffer, JM ;
Smith, RG ;
Moller, DE .
MOLECULAR ENDOCRINOLOGY, 1998, 12 (10) :1594-1604
[34]   Peroxisome proliferator-activated receptor structures: Ligand specificity, molecular switch and interactions with regulators [J].
Zoete, Vincent ;
Grosdidier, Aurelien ;
Michielin, Olivier .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2007, 1771 (08) :915-925